K2 BioLabsPonce TherapeuticsPortfolioRapha Capital Management Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin
K2 BioLabsPonce TherapeuticsPortfolioRapha Capital Management New Biotechnology Research Accelerator Launches in Houston
PortfolioRapha Capital Management Rapha Capital Management Announces First Managed Venture Fund Focused on Investment in Early-Stage Biotech Startups
PortfolioRapha Capital Management Rapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc.
Ponce TherapeuticsPortfolioRapha Capital Management Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin
PortfolioRapha Capital Management AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME)
PortfolioRapha Capital Management NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor
PortfolioRapha Capital Management Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
